62 results about "Metabolic Marker" patented technology

This invention belongs to the field of diagnostic testing technology. Addressing the problem that existing gestational diabetes screening methods may miss the optimal time for early intervention, leading to the failure to promptly detect and manage some potentially hyperglycemic pregnant women, increasing the risk of adverse maternal and fetal outcomes, this invention proposes a plasma metabolic biomarker for the early diagnosis or prediction of gestational diabetes and its application. This plasma metabolic biomarker is at least one of L-lysine, propargylglycine, N6-acetyl-L-lysine, cyclic leucine, and glycine-deoxycholic acid. The five plasma metabolic biomarkers provided by this invention can be applied to the early diagnosis or prediction of gestational diabetes, and are of great significance for the prevention or treatment of gestational diabetes.

This invention provides a combination of metabolic biomarkers for T-staging assessment of colorectal cancer, comprising four groups of metabolite combinations specifically distinguishing different T stages of colorectal cancer, each group containing 10 endogenous small molecule metabolites. This invention also provides detection methods and applications for the above-mentioned metabolic biomarker combinations. Furthermore, this invention provides a method for T-staging colorectal cancer for non-diagnostic and therapeutic purposes, as well as a combination of metabolic biomarkers related to the evolution of T-staging and tumor invasion depth in colorectal cancer. The advantages of this invention are: by combining iEESI-MS detection with multivariate statistics and machine learning, specific metabolic biomarkers related to T-staging of colorectal cancer are screened, a T-staging discrimination model is constructed, and objective, accurate, and rapid assessment of T-staging of colorectal cancer is achieved, providing molecular support for preoperative individualized treatment.

The application relates to application of phosphatidylinositol and phosphatidylglycerol as metabolic markers for predicting intracranial atherosclerosis progression, and belongs to the technical field of medical biological detection. In the scheme, single-sample MR analysis is carried out by combining RICAS cohort data with external database data, causal correlation between metabolites and ICAS is analyzed, and serum biomarkers phosphatidylinositol PI 18:0 / 22:6 and phosphatidylglycerol PG 18:1 / 18:2 for ICAS occurrence and development are screened out by combining characteristic metabolic changes of ICAS with causal correlation analysis. ICAS progression is collected through prospective follow-up of the RICAS cohort, the correlation between the serum biomarkers and the ICAS progression is established, and it is verified that the serum biomarkers have transformation application value and can be used as a new biomarker for early prediction of ICAS progression and derivation.

The application discloses that 5-oxoproline can be used as a biomarker for diagnosing chemotherapy-induced cardiomyopathy, and for the first time provides a blood metabolic marker for assisting in predicting and early diagnosing chemotherapy drug-induced cardiomyopathy, which has high accuracy and diagnostic reference value. By accurately determining the content of the small molecule metabolic marker 5-oxoproline in blood, the diagnosis of early myocardial injury induced by chemotherapy drugs will no longer completely rely on conventional non-specific myocardial injury markers and imaging methods, but will rely on the content change of metabolic products in the blood of patients as an objective index, thus advancing the time window for discovering subclinical myocardial injury, significantly improving the early diagnosis detection rate, simplifying the diagnosis process, providing an opportunity for early intervention, helping to prevent or reverse the further aggravation of chemotherapy-induced cardiomyopathy, and thus improving the overall survival prognosis of tumor patients.

This invention discloses a method and system for embryo quality detection, relating to the field of embryo detection technology, including the following steps: S1: fertilized embryos are continuously cultured in an in vitro culture system containing specific metabolic marker detection components, and continuous dynamic imaging of the embryos is performed to obtain a complete dynamic developmental image sequence; S2: the dynamic developmental image sequence is segmented, and temporal developmental features are captured, identifying key time points such as pronucleus appearance and disappearance, cleavage, and blastocyst formation, and generating a segmentation mask corresponding to each frame of the dynamic developmental image sequence; this invention achieves full-process time-difference imaging to capture the temporal features of embryonic development, without trauma or interference, avoiding subjective bias in static observation; by segmenting the dynamic developmental image sequence and capturing temporal developmental features, the segmentation accuracy is high and the anti-interference ability is strong.

The invention relates to the technical field of liquid chromatography / mass spectrometry analysis, and discloses a method for improving LC / MS analysis sensitivity, which is suitable for detecting trace lipid metabolites (containing isomeride) of a biological sample. The core technical scheme is as follows: a magnetic molecularly imprinted polymer-solid phase support liquid-liquid extraction secondary purification system is adopted to remove matrix impurities, a gradient mobile phase containing a composite additive is matched to optimize separation, and the detection specificity is improved by an ion mobility spectrometry-segmented selective ion monitoring combined mode; and a stable isotope internal standard is synchronously introduced to correct quantitative deviation. Experiments show that the LOD of the method is as low as 0.12-0.25 ng / mL, the matrix effect is smaller than or equal to 5%, the separation degree and the recovery rate are excellent, low-abundance metabolic marker differences can be accurately captured, and a support is provided for disease diagnosis and metabonomics research.

The application discloses a metabolic marker, a screening method and application related to gout combined with uric acid nephrolithiasis, and belongs to the technical field of biology. The application analyzes the significant differences of metabolic small molecules in the serum of asymptomatic hyperuricemia and gout combined with uric acid nephrolithiasis patients through a metabolomics method, screens metabolic markers that can be used for predicting gout combined with uric acid nephrolithiasis, and further verifies the sensitivity, specificity and accuracy of the metabolic markers. These findings not only provide markers for early diagnosis and precise treatment of gout combined with uric acid nephrolithiasis, but also provide important basis for understanding the clinical heterogeneity of hyperuricemia and the evolution mechanism thereof.

The invention relates to the technical field of biologic detection of metabolomics, in particular to an OSAHS metabolism marker, a diagnosis model and application of the OSAHS metabolism marker and the diagnosis model. The metabolic marker comprises a red blood cell metabolite and / or a plasma metabolite; erythrocyte metabolites comprise L-aspartic acid, D-ribose-5-diphosphoric acid, cadaverine, 12, 13-epoxy octadecenoic acid, L-arginine, N-acetylmethionine, 5-hydroxyeicosatetraenoic acid, 13-oxo-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 10-tetrahydroxy-9Z, the component A is one or more of 11E-octadecadienoic acid, inosine monophosphate, nicotinamide, alpha-lactose, sphingosine, hydroxy octadecadienoyl or glyceraldehyde-3-phosphoric acid; the plasma metabolite is prepared from one or more of fumaric acid, cadaverine, L-aspartic acid, malic acid, sphingosine-1-phosphoric acid, L-arginine, cysteine-S-sulfate, thiosulfate, gamma-glutamyl alanine, galacturonic acid or vitamin B2.

This invention relates to an early selection and evaluation method for salt tolerance in grass carp based on serum metabolic markers. The method includes: (1) calculating the salinity sensitivity coefficient based on the serum metabolic markers obtained through screening: SSC = (normal control group index value - salinity treatment group index value) / normal control group index value, the larger the value, the more sensitive the fish; (2) calculating the fuzzy membership index based on the SSC value; (3) calculating the weight coefficient of each serum metabolic marker based on principal component analysis. w =Contribution rate of a single indicator / Cumulative contribution rate of principal components; (4) Calculate the comprehensive evaluation value of grass carp's salinity sensitivity based on fuzzy membership index and serum metabolic marker weight coefficient; (5) Salt tolerance assessment: In the early salt tolerance assessment, the higher the comprehensive evaluation value of salinity sensitivity, the worse the salt tolerance. This method can achieve accurate assessment of grass carp's salinity sensitivity by detecting and analyzing the dynamic changes of specific serum metabolic markers.

The invention relates to the technical field of biological medicine, and discloses a biomarker for predicting COPD cognitive impairment and application of the biomarker. The invention finds and verifies that the specificity of stearic acid (SA) in serum and a key enzyme ELOVL6 synthesized by the stearic acid (SA) in serum in a patient with secondary cognitive impairment (CI) of chronic obstructive pulmonary disease (COPD) is improved for the first time, the level of the stearic acid (SA) and the key enzyme ELOVL6 is negatively correlated with the cognitive impairment degree, and the stearic acid (SA) and the key enzyme ELOVL6 have good prediction efficiency (AUCgt, 0.82) on the COPD-CI. On the basis, the invention provides the application of the serum SA and / or ELOVL6 as the biomarker for predicting the COPD secondary CI risk, the in-vitro diagnostic kit comprising the detection reagent of the biomarker, and the method for predicting the risk by detecting the level of the marker. The invention provides a brand-new and reliable metabolic marker tool for early warning and intervention of CI of COPD patients, and has important clinical value and transformation prospect.

The application discloses a negative ion metabolic marker related to adolescent depression, a product and an application. The metabolic marker comprises any one or several of the following: Homogentisic acid, Aurantio-obtusin, 3-o-acetyl-16alpha-hydroxytrametenolic acid, Leoidin and Kynurenic acid. The application provides a kit comprising detection reagents for detecting the negative ion metabolic marker. The application provides a computer program product related to adolescent depression. The product provided by the application has good feasibility and accuracy, can effectively evaluate the risk of adolescent depression, and provides a new tool for clinical diagnosis.

The invention provides application of a group of plasma metabolism markers in preparation of a reagent product for pulmonary nodule diagnosis, and relates to the technical field of disease diagnosis reagents. The metabolic marker is prepared from trigonelline, 4-methylcatechol, 2, 4-dinitrophenol, 3, 4-dihydroxyphenylacetic acid, N-(2-furfuryl) glycine, mevalonic acid and formononetin, and the metabolic marker is prepared from the following raw materials: the trigonelline, the 4-methylcatechol, the 2, 4-dinitrophenol, the 3, 4-dihydroxyphenylacetic acid, the N-( According to the application, ultra-high performance liquid chromatography-high resolution mass spectrometry (UPLC / MS) is adopted to carry out metabonomics analysis on plasma samples before and after an early pulmonary nodule operation, and a group of plasma metabolites (trigonelline, 4-methylcatechol, 2, 4-dinitrophenol, 3, 4-dihydroxyphenylacetic acid, N-(2-furfuryl) glycine, mevalonic acid and formononetin) are identified; and the group of metabolites is utilized to form a diagnosis model, so that benign and malignant pulmonary nodules can be accurately diagnosed, and early-stage differential diagnosis and risk assessment are facilitated.

The invention relates to the technical field of metabonomics analysis, in particular to application of a metabolic marker in preparation of a head and neck squamous cell carcinoma diagnostic product, a kit, a screening method of the metabolic marker of the head and neck squamous cell carcinoma, a diagnostic model and a construction method and application of the diagnostic model. The metabolic marker comprises at least one of lactic acid, sphingosine, cadaverine, uridine diphosphate, allantoic acid, hydroxyproline, sphingosine-1-phosphoric acid, indole-3-acetaldehyde, pantothenic acid, fumaric acid, malic acid, prostaglandin or ornithine in red blood cells and / or plasma. The screened red blood cells and plasma metabolism markers can be used for predicting or diagnosing the head and neck squamous cell carcinoma respectively or independently, particularly, the red blood cell metabolism markers can provide more stable tumor microenvironment information, and the metabolism stability is high and is not easily influenced by diet and circadian rhythm.

The application discloses a method for simultaneously detecting retinoids and lipid-soluble vitamin metabolic marker groups in biological samples and matching reagents. The application is based on magnetic bead solid-phase extraction technology, significantly improves sample purification effect, and reduces matrix interference; in combination with a high-aqueous-phase reversed-phase chromatography system and a positive-negative ion switching multi-reaction monitoring mode, simultaneous separation and detection of seven retinoid molecules and a full spectrum of lipid-soluble vitamins are realized. The method has high sensitivity, strong specificity and wide detection range, and for the first time realizes one-stop analysis across species and sample types, thereby providing reliable platform support for clinical and scientific research applications.

The invention belongs to the crossing field of traditional Chinese medicine modernization and biotechnology, and particularly relates to application of a metabolic marker in preparation of a product for auxiliary diagnosis of retinal vein occlusion (RVO) or evaluation of prognosis of treatment of RVO by ginseng-wolfberry omentum granules. The metabolic marker is selected from at least one of the following metabolites: leukotriene B4, (R)-2-feruloyl-1-(4-hydroxyphenyl)-1, 2-ethylene glycol, hyoscyamine base A6, 11, 12-epoxyeicosatrienoic acid, 3, 3 ', 4, 4'-tetrahydroxy-5, 6, 7, 8, 9, 10, 11, 12-epoxyeicosatrienoic acid, 3, 3 ', 4, 4'-tetrahydroxyl-5, 6, 7, 8, 10-tetrahydroxyl-5, 7, 8, 10 The invention relates to an anti-inflammatory agent which is prepared from 5, 5 '-diisopropyl-2, 2'-dimethyl biphenyl (3, 3 ', 4, 4', 1-ethyl piperidine, flavin mononucleotide, crystal orchid glycoside, 2-O-caffeoyl arbutin, dimethyl ellagic acid glucuronide, 4 '-hydroxy-3, 4, 5-resveratrol trimethyl ether, 3'-methoxy petamicin, phenylalanyl-leucyl-isoleucyl-tyrosine and dihydroferulic acid-4-sulfate.

This invention discloses urinary metabolic biomarkers for hyperuricemia and their applications, relating to the field of metabolomics technology. It aims to overcome the shortcomings of traditional serum uric acid detection, such as susceptibility to interference, insufficient early warning capabilities, and a lack of sensitive, specific, and non-invasive biomarkers. The urinary metabolic biomarker is at least one of L-kynurenine, indole, and betaine, which can be used to prepare reagents or kits. The assessment system includes a sample analysis unit and a risk assessment model. This invention enables non-invasive and convenient detection of hyperuricemia, accurately captures early metabolic abnormalities, provides reliable risk stratification, and supports clinical auxiliary diagnosis and pathogenesis research.

The application discloses a plasma metabolic marker composition and a screening method and application thereof, and relates to the technical field of biomedicine. The plasma metabolic marker composition comprises glycyl-L-glutamic acid, phosphatidylcholine 38:7, pyrrole-2-formic acid and phosphatidylethanolamine 36:2p. The metabolic marker composition is significantly different in different cancer types, can distinguish different cancer types of cancer patients, and realizes the detection of pan-cancer. The metabolic marker composition is non-invasive and minimally invasive when used for the detection of pan-cancer, is more suitable for the screening and detection of a large number of ordinary people, has high sensitivity and specificity, is more suitable for the early screening of cancer, and is helpful for the early screening, early diagnosis and early treatment of cancer, and is helpful for improving the survival rate and cure rate of cancer patients.

The invention belongs to the technical field of food processing and quality safety control, and particularly relates to a specific metabolic marker combination for identifying a drying mode of high-calcium vegetable ox ear powder and application of the specific metabolic marker combination. The metabolic marker composition is prepared from 12 kinds of metabolites, namely, larch sibirica flavone, 9-Methyl-arylchromenone, larch resinol, docosapentaenoic acid, gibberellin A7, methyl-arylpyranone, docosapentaenoyl glycerophosphorylcholine, Cratoxyborenone E, heptanol, prenylflavonoids, pteridin-6-carboxylic acid and Garcimangosone B. The invention further discloses a preparation method of the metabolic marker composition. The metabolic marker combination provided by the invention can be used for carrying out production process traceability and authenticity identification on the high-calcium vegetable ox ear powder, and can be used as a basis for evaluating a product drying process quality standard and monitoring the consistency of a drying process.

The invention provides a metabolic marker composition for distinguishing health from breast cancer. Based on metabonomics data of blood plasma, a blood plasma metabolism marker combination for breast cancer diagnosis is screened, and a breast cancer diagnosis model with relatively high sensitivity and specificity is constructed in combination with a machine learning algorithm. The method has high sensitivity and specificity, samples are convenient to obtain, non-invasive performance is achieved, accurate screening of the breast cancer can be achieved, important help is provided for prevention of the breast cancer and reduction of the morbidity, and the method is suitable for large-scale population screening and long-term tracking in areas with shortage of medical resources.

The invention discloses a serum metabolism marker combination for ectopic pregnancy diagnosis and rupture risk prediction and application of the serum metabolism marker combination, and relates to the technical field of biological science. The metabolic fingerprint diagnosis model (AUCgt, 0.91) and the metabolic marker panel (AUCgt, 0.92) have the advantages that the performance of the metabolic fingerprint diagnosis model (AUCgt, 0.91) and the performance of the metabolic marker panel (AUCgt, 0.92) are obviously superior to those of an existing'ultrasonic + beta-hCG 'diagnosis mode, the problems of diagnosis delay, misdiagnosis and missed diagnosis clinically at present are effectively solved, and the clinical rigid requirements of early and accurate diagnosis are met; the fracture risk prediction model AUC 0.885 constructed by the method disclosed by the invention fills the current clinical blank. Key decision support can be provided for doctors, early intervention on high-risk patients is achieved, excessive medical treatment on low-risk patients is avoided, and the mortality risk of pregnant and lying-in women is reduced. According to the invention, based on the nanoparticle-assisted laser desorption / ionization mass spectrometry technology, ultra-fast detection of only about 3 seconds for single sample detection is realized, and the method is expected to become a fast detection tool in emergency treatment and outpatient service scenes.

The invention provides a metabolic marker composition for distinguishing benign thyroid diseases from thyroid cancer and application of the metabolic marker composition. Based on blood metabonomics data, a diagnosis model capable of accurately distinguishing benign thyroid diseases and thyroid cancer is constructed by screening a specific metabolic marker combination and combining a machine learning algorithm, and the model has relatively high sensitivity and specificity. Based on the constructed diagnosis model, whether the patient suffers from the thyroid cancer or the benign thyroid disease can be judged at the same time only through one-time detection, excessive examination of the patient suffering from the benign thyroid disease can be avoided, excessive diagnosis and treatment are reduced, and excessive panic of the patient is avoided. The thyroid cancer diagnosis model method provided by the invention has the advantages of convenience, economy and convenience in sample acquisition, and is more suitable for large-scale population screening and regular tracking in regions with shortage of medical resources.

The invention relates to the technical field of biomedicine, and particularly discloses an in-vitro diagnosis marker for gall-stone and application thereof.The in-vitro diagnosis marker is jointly composed of a metabolism marker and an inflammation marker, the metabolism marker is the concentration ratio of lithocholic acid to ursodesoxycholic acid (LCA / UDCA), and the inflammation marker is the concentration ratio of CD133 to lipopolysaccharide (CD133 / LPS); the invention further provides a kit containing the marker and a detection method of the kit. The kit integrates specific detection reagents for LCA, UDCA, CD133 and LPS, two specific value markers can be rapidly, sensitively and simultaneously detected through an optimized sample treatment and detection process, and result judgment is carried out based on a preset reference interval upper limit and a composite judgment rule.

The invention provides a urine metabolism marker combination for distinguishing kidney benign diseases and kidney cancer and application of the urine metabolism marker combination, and belongs to the technical field of biomarkers. The urine metabolism marker combination for distinguishing the kidney benign disease from the kidney cancer comprises at least two of the following components: (S)-2-piperidine-6-carboxylic acid, 2 '-deoxyguanosine, 3-hydroxybutyric acid, 6-aminocaproic acid, glycyl-L-proline, glycyl-gamma-aminobutyric acid, L-cysteine sulfinic acid and N, N-dimethyl formamide. The amino acid sequence is shown in the specification, and the amino acid sequence is shown in the specification. The amino acid sequence is shown in the specification, namely, N, N-dimethyl glycine, N-acetyl-L-glutamic acid, L-methionine-L-aspartic acid, 2-oxoglutaric acid and glycine chenodeoxycholic acid. Model construction and verification analysis show that the AUC values of diagnosis models constructed by combining different quantities of metabolite markers are all greater than 0.8, the sensitivity is greater than 0.7, and the specificity is greater than 0.7. Therefore, based on the urine metabolism marker combination screened by the invention, the kidney benign disease and the kidney cancer can be efficiently and accurately distinguished.

The invention relates to the technical field of cancer diagnosis and treatment, ENPP2 acetylation is used as a diagnostic marker, the diagnostic marker is used for screening diagnosis and prognosis evaluation of early-onset colorectal cancer (EOCRC) through peripheral blood quantitative detection, the sensitivity and the specificity of the diagnostic marker are remarkably improved compared with those of a traditional marker CEA, and a more accurate metabolic marker is provided for early-stage noninvasive diagnosis of EOCRC. Besides, the molecular mechanism that the ENPP2 regulates and controls the P53 signal channel through acetylation modification is clarified for the first time, animal experiments verify that the ENPP2 inhibitor PF8380 can specifically reverse the corresponding mechanism so as to inhibit EOCRC progress, a brand new treatment strategy targeting the ENPP2-P53 channel is provided for clinic, and the application is particularly suitable for overcoming drug resistance of traditional chemotherapy. The marker combination provided by the invention has both diagnosis accuracy and treatment innovativeness, and provides a breakthrough solution for whole-course management of EOCRC (Ethernet over Cyclic Redundancy Check).

The application provides a metabolic marker combination for early kidney cancer diagnosis and application thereof, and belongs to the technical field of in vitro diagnosis. The metabolic marker combination for early kidney cancer diagnosis comprises a first combination or a second combination. The first combination comprises glycyl-L-glutamic acid, L-glutamyl-L-serine, methylphosphatidylcholine 33:2e and triglyceride 54:7. The second combination comprises glycyl-L-glutamic acid, L-glutamyl-L-serine, L-threonyl-L-aspartic acid, iminodiacetic acid, triglyceride 56:8, O-phosphoethanolamine, methylphosphatidylcholine 33:2e and triglyceride 54:7. By detecting the metabolic marker combination in a blood sample, it can be determined whether a patient has early kidney cancer, has high sensitivity and specificity, can realize precise screening of early kidney cancer, and provides important help for prevention and reduction of the incidence of kidney cancer.

The application discloses a combined metabolic marker and detection kit for mitochondrial purity evaluation, the marker comprises phosphatidylcholine PC 34:0 (16:0 / 18:0), sphingomyelin SM 34:1;2O (d18:1;2O / 16:0), sphingomyelin SM 44:2;2O (18:1;2O / 24:1) and hexosylceramide HexCer 42:2;2O (d18:1;2O / 24:1), and is used for judging the new application and kit of mitochondrial purity of mitochondria extracted by a mitochondrial extraction method. The application judges the mitochondrial purity extracted by the method by detecting the relative concentrations of four lipid metabolites in the mitochondrial sample, calculating a combined marker variable P based on a binary logistic regression equation and determining a cut-off value. The kit can realize high-sensitivity and high-efficiency detection of the four small molecule metabolites, and has the characteristics of low detection cost and good repeatability.

The invention discloses a metabolic marker combination, a kit for detecting the metabolic marker combination and application of the metabolic marker combination, and particularly relates to a metabolic marker combination for auxiliary diagnosis of liver cancer, a kit for detecting the metabolic marker combination and application of the metabolic marker combination. The metabolic marker combination comprises glycocholic acid, sebacic acid, phenylalanyl tryptophan, arachidonic acid and alpha-linolenic acid. The metabolic marker combination has high accuracy, sensitivity and specificity when used for detecting the liver cancer or predicting the liver cancer risk, can be used for developing a rapid liver cancer detection kit, and provides a new early risk assessment scheme for patients or susceptible people.

The invention discloses a metabolism marker related to the calving interval length of dairy cows and application of the metabolism marker, and belongs to the technical field of animal husbandry biological breeding. The metabolic marker is phenylalanyltryptophan, and the metabolic marker is phenylalanyltryptophan, and the metabolic marker is phenylalanyltryptophan, phenylalanyltryptophan and phenylalanyltryptophan. For cows with long calving intervals of more than 410 days, compared with cows with short calving intervals of less than 365 days, the content of phenylalanyl tryptophan in plasma is remarkably reduced. By detecting the metabolic marker, the efficient analysis and prediction of the long and short calving interval of the dairy cow can be realized, so that an auxiliary decision-making tool is provided for the breeding of high-fecundity breeding cows.